Dr Keiichi Fujiwara joins touchONCOLOGY to discuss his thoughts on the latest clinical trial highlights at European Society for Medical Oncology (ESMO) 2022 in gynaecological cancers, specifically the GOTIC-002 LUFT study.
- What are the hot topics and clinical trial highlights in gynaecological cancer from ESMO?
Disclosures: Keiichi Fujiwara receives grant/research support from Taiho; is on the advisory board for Daiichi Sankyo, Seagen, and Genmab; and receives honoraria/honorarium from Kiowa KIRIN.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Gynaecological Cancers
Navigating HRT and cancer risk: PrEvCan | Celia Diez de los Rios
This July, the PrEvCan campaign is dedicated to raising awareness about women’s cancer risk in connection with breastfeeding and hormone replacement therapy (HRT). Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of […]
Cancer prevention and the power of breastfeeding: PrEvCan | Celia Diez de los Rios
The relationship between breastfeeding and a reduction in cancer risk is the focus of the PrEvCan Campaign, this July. Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of cancer. In this interview […]
Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial – Olaparib for the treatment of advanced ovarian cancer – Overall survival findings at 7 years
The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!